title: Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial.
abstract: BACKGROUND
  The efficacy of current topical acne treatments in mitigating the potential for acne scarring is not known.
  
  
  OBJECTIVE
  To evaluate the effect of adapalene 0.1%/benzoyl peroxide 2.5% (A/BPO) gel compared to vehicle in reducing the risk of acne scarring.
  
  
  METHODS
  Multicentre, randomized, investigator-blinded, vehicle-controlled, split-face study conducted over 6 months. Subjects were adults with active moderate facial acne vulgaris and at least 10 atrophic acne scars at baseline. Efficacy evaluations included counts of atrophic acne scars and primary acne lesions as well as a Scar Global Assessment (SGA; 5-point scale).
  
  
  RESULTS
  After 6 months treatment, scar counts remained stable with A/BPO while increasing by approximately 25% with vehicle (mean scar count 11.58 vs. 13.55, respectively, at Month 6; P = 0.036). The percentage of subjects with a SGA of 'almost clear' (hardly visible scars) increased from 9.7% to 45.2% with A/BPO, whereas it did not change with vehicle (P = 0.0032). Total acne lesion counts decreased by 65% with A/BPO and 36% with vehicle (mean lesion count 8.5 vs. 16.1, respectively, at Month 6; P < 0.001).
  
  
  CONCLUSIONS
  Relatively small study group (31 subjects).
  
  
  CONCLUSIONS
  Topical long-term treatment with A/BPO is effective in reducing the risk of atrophic scars and improving the global severity of scarring.
authors: CHU Nantes, Nantes, France.
authors: B
authors: B
authors: Dreno
authors: Windsor Clinical Research Inc. and Western University, Windsor, ON, Canada.
authors: J
authors: J
authors: Tan
authors: Galderma R&D, Sophia Antipolis, France.
authors: M
authors: M
authors: Rivier
authors: Galderma R&D, Sophia Antipolis, France.
authors: P
authors: P
authors: Martel
authors: Innovaderm Research, Montreal, QC, Canada.
authors: R
authors: R
authors: Bissonnette
mesh_terms: D000152:Acne Vulgaris / Q000150:complications / Q000188:drug therapy*; D000068801:Adapalene, Benzoyl Peroxide Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001284:Atrophy / Q000209:etiology / Q000517:prevention & control; D002921:Cicatrix / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005148:Facial Dermatoses / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D016037:Single-Blind Method; D055815:Young Adult
chemical_list: D000068801:Adapalene, Benzoyl Peroxide Drug Combination; D003879:Dermatologic Agents; D005782:Gels